Cargando…
Cabergoline reduces 3-methoxytyramine in a SDHC patient with metastatic paraganglioma and prolactinoma
SUMMARY: We observed a novel therapeutic response with cabergoline in a male patient with a dopamine-secreting head and neck paraganglioma (HNPGL), macroprolactinoma and germline succinate dehydrogenase C mutation (SDHC). The macroprolactinoma was treated with cabergoline which gave an excellent res...
Autores principales: | Hussein, Ziad, Korbonits, Marta, Baldeweg, Stephanie E, Chung, Teng-Teng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240717/ https://www.ncbi.nlm.nih.gov/pubmed/34110302 http://dx.doi.org/10.1530/EDM-21-0003 |
Ejemplares similares
-
Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline
por: Almistehi, Wael M, et al.
Publicado: (2018) -
A macroprolactinoma becoming resistant to cabergoline and developing
atypical pathology
por: Sbardella, Emilia, et al.
Publicado: (2016) -
Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour
por: Abell, Sally K, et al.
Publicado: (2015) -
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
por: Hakami, Osamah A, et al.
Publicado: (2019) -
New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer
por: Cunha, Clara, et al.
Publicado: (2022)